Sbierski-Kind, Julia
Schlickeiser, Stephan
Feldmann, Svenja
Ober, Veronica
Grüner, Eva
Pleimelding, Claire
Gilberg, Leonard
Brand, Isabel
Weigl, Nikolas
Ahmed, Mohamed I. M.
Ibarra, Gerardo
Ruzicka, Michael
Benesch, Christopher
Pernpruner, Anna
Valdinoci, Elisabeth
Hoelscher, Michael
Adorjan, Kristina
Stubbe, Hans Christian
Pritsch, Michael
Seybold, Ulrich
Roider, Julia
,
Funding for this research was provided by:
German Research Foundation
German Diabetes Society
FoeFoLe, LMU Munich
German Society of Internal Medicine
German Center for Infection Research
Else Kröner-Fresenius-Stiftung (EKFS).
Ludwig-Maximilians-Universität München
Article History
Received: 13 November 2023
Accepted: 19 December 2023
First Online: 7 February 2024
Declarations
:
: The authors declare no commercial or financial conflicts of interest.
: KoCo19-Shield: The study protocol was reviewed and approved by the Institutional Review Board of the Medical Faculty at Ludwig-Maximilians-University Munich, Germany under the project number 20-692 (vote of approval dated Sept. 21st, 2020) and 20-371 (vote of approval dated May 15th, 2020). Oral and written informed consent was obtained from all study subjects. PCC: The study protocol was reviewed and approved by the Institutional Review Board of the Medical Faculty at Ludwig-Maximilians-University Munich, Germany under the project number 21-1165 (vote of approval dated Feb 15, 2021, amendment approved Aug. 11, 2021). Oral and written informed consent was obtained from all study subjects.
: The patients/participants provided their written informed consent to participate in this study.